New hope for blinding eye disease: experimental drug SCT520FF enters human trials
NCT ID NCT06672536
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 32 times
Summary
This study tests a new medicine called SCT520FF for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive the drug to see if it is safe and can help control the disease. The goal is to reduce fluid buildup in the eye and improve or stabilize eyesight.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAMD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Medical University Eye Hospital
RECRUITINGTianjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.